Blue KC Pathogen Panel Testing Coverage Update

Coverage Criteria

Covered outpatient pathogen panel testing

Covered when ALL of the following are met (outpatient setting):

Gastrointestinal panels: For individuals with persistent diarrhea or diarrhea with signs or risk factors for severe disease (e.g., fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain), multiplex PCR-based gastrointestinal pathogen panel testing (up to 11 targets) may be reimbursed.<=11 targets; frequency: once every 7 days

Outpatient only; frequency limit: no more often than once every 7 days

Respiratory panels - general: For individuals displaying signs and symptoms of a respiratory tract infection (see Note 1), antigen panel testing or multiplex PCR-based respiratory panel testing of up to 5 respiratory pathogens may be reimbursed.<=5 targets

Outpatient only; see Note 1 for signs/symptoms

Respiratory panels - immunocompromised: For immunocompromised individuals displaying signs and symptoms of a respiratory tract infection (see Note 1), multiplex PCR-based respiratory panel testing of up to 25 respiratory pathogens may be reimbursed.<=25 targets; immunocompromised status required

Outpatient only; documentation of immunocompromised status required

Not medically necessary / Not reimbursed

Not covered (may be denied):

Not reimbursed - GI large panels: Multiplex PCR-based gastrointestinal panel testing of 12 or more targets is not reimbursed.>=12 targets

See CPT 87507

Not reimbursed - respiratory large panels: In situations not described in the covered criteria, antigen panel testing or multiplex PCR-based respiratory panels of 6 or more pathogens may not be reimbursed.>=6 targets (unless immunocompromised exception applies)

Not reimbursed - CSF and blood panels: Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF) is not reimbursed, and molecular detection-based panel testing of pathogens in blood is not reimbursed.specimen type exclusions

This policy applies to outpatient multiplex polymerase chain reaction (PCR)-based pathogen panel testing and sets limits by specimen type and panel size. Coverage is dependent on the member's benefit at the time of the request and applies only in the outpatient setting. For gastrointestinal indications, multiplex PCR-based GI panels of up to 11 targets may be reimbursed for individuals with persistent diarrhea or diarrhea with signs or risk factors for severe disease, with a frequency limit of no more often than once every 7 days. For respiratory syndromes, antigen panels or multiplex PCR panels of up to 5 respiratory targets may be reimbursed for individuals with signs/symptoms of respiratory tract infection; an exception allows up to 25 respiratory targets only for immunocompromised individuals displaying respiratory signs/symptoms. Panels that exceed these target limits or are performed in excluded specimen types are subject to non-reimbursement per the criteria below.

Molecular-based panel testing intended for broad, general microbial screening — for example, combined qPCR plus next-generation sequencing platforms such as MicroGenDX qPCR+NGS — does not meet coverage criteria and may not be reimbursed due to a lack of published evidence demonstrating clinical benefit for routine diagnostic use.

Covered Indications

Persistent diarrhea or diarrhea with signs/risk factors for severe disease

Covered when ALL of the following are met (outpatient setting):

GI multiplex PCR: Individual has persistent diarrhea or diarrhea with signs or risk factors for severe disease (e.g., fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain).

Clinical documentation must support symptoms

Test type and size: Order is for a multiplex PCR gastrointestinal pathogen panel of up to 11 targets.<=11 targets

Frequency: Testing is requested no more often than once every 7 days.frequency: once every 7 days

Frequency Limits

Frequency limits: GI multiplex PCR panel (<=11 targets)

TestMultiplex PCR gastrointestinal pathogen panel (up to 11 targets)

Frequency limitNo more often than once every 7 days

SettingOutpatient only

Covered indicationPersistent diarrhea or diarrhea with signs/risk factors for severe disease (e.g., fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain)

Coding

Listed CPT/Proprietary Codesmixed

87154	Culture, typing; identification of blood pathogen and resistance typing, when performed, by nucleic acid (DNA or RNA) probe, multiplexed amplified probe technique including multiplex reverse transcription, when performed, per culture or isolate, 6 or more targets.
87428	Infectious agent antigen detection by immunoassay technique; SARS-CoV and influenza A/B.
87483	Infectious agent detection by nucleic acid; central nervous system pathogen, 12-25 targets.
87505	Infectious agent detection by nucleic acid; gastrointestinal pathogen, 3-5 targets.
87506	Infectious agent detection by nucleic acid; gastrointestinal pathogen, 6-11 targets.
87507	Infectious agent detection by nucleic acid; gastrointestinal pathogen, 12-25 targets.
87631	Respiratory virus nucleic acid detection, 3-5 targets.
87632	Respiratory virus nucleic acid detection, 6-11 targets.
87633	Respiratory virus nucleic acid detection, 12-25 targets.
87636	SARS-CoV-2 and influenza A/B, multiplex amplified probe technique.

1–10 of 37

1/4

Gastrointestinal pathogen panel size (coding threshold)

Covered sizeUp to 11 gastrointestinal pathogen targets (87505/87506 range)

Not covered size12 or more gastrointestinal pathogen targets (CPT 87507)

Covered indicationPersistent diarrhea or diarrhea with signs/risk factors for severe disease; outpatient setting

Respiratory pathogen panel size (coding threshold)

Standard coverageAntigen panel testing or multiplex PCR-based panels of up to 5 respiratory pathogens are reimbursable for individuals with respiratory infection signs/symptoms

Immunocompromised exceptionFor immunocompromised individuals with respiratory infection signs/symptoms, multiplex PCR panels up to 25 respiratory pathogens may be reimbursed

Provider Actions and Billing Guidance

Documentation Required

Benefit and setting dependency

Coverage and billing depend on the member's benefit at time of service and testing must occur in the outpatient setting. Document clinical signs/symptoms and, when applicable, immunocompromised status to support medical necessity. Final reimbursement is subject to member eligibility, benefit limits, and applicable claims adjudication edits.

Service must be outpatient and benefits verified at time of request.
Document signs/symptoms and immunocompromised status when applicable.

Billing Rule

Panels exceeding size limits

Do not expect reimbursement for panels that exceed specified size limits unless an exception applies. Gastrointestinal panels that include 12 or more gastrointestinal pathogens (GIPs) will not be reimbursed. Respiratory antigen or multiplex panels of 6 or more respiratory pathogens will not be reimbursed except when performed on immunocompromised individuals with signs/symptoms of respiratory infection (in which case multiplex PCR-based panels up to 25 respiratory pathogens may be reimbursed). For persistent diarrhea or diarrhea with severe features, multiplex PCR-based GI panels of up to 11 targets may be reimbursed no more often than once every 7 days.

Ordering Requirements

Step Therapy

Order only after benefit verification and document clinical indications

Only order outpatient pathogen panel testing after verifying member benefits and outpatient eligibility. Ensure the medical record documents the clinical signs/symptoms that justify testing and document immunocompromised status when ordering larger respiratory panels.

Verify member eligibility and benefit coverage prior to ordering.
Record clinical signs/symptoms (e.g., persistent diarrhea, respiratory infection signs per Note 1).
Document immunocompromised status when requesting respiratory panels beyond standard size.

Not Covered

The following categories of testing are not covered / may be denied: multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF); molecular detection–based panel testing of pathogens in the blood; molecular detection–based panel testing of urine for UTI diagnosis (e.g., GENETWORx); molecular-based panel testing to screen for or diagnose wound infections (e.g., GENETWORx PCR Wound Testing); and broad molecular general microbial screening platforms (e.g., MicroGenDX qPCR+NGS). Additionally, multiplex PCR gastrointestinal panels of 12 or more targets and respiratory antigen or multiplex panels of 6 or more targets (unless covered under the immunocompromised exception) may not be reimbursed.

Background

Multiplex PCR and amplified-probe techniques enable simultaneous detection of multiple infectious agents from a single specimen, often with higher analytic sensitivity and faster turnaround than culture or some immunoassays. This policy recognizes those capabilities but limits reimbursement by specimen type and by panel size to reflect available evidence and clinical utility in the outpatient setting. Clinical documentation of signs/symptoms (and immunocompromised status when requesting expanded respiratory panels) is required to support coverage.

Definitions

Respiratory infection signs and symptoms (Note 1)

Common systemic signsFever, chills, fatigue, headache, myalgia, weakness

Upper respiratory signsCough, rhinorrhea, pharyngitis, sore throat, nasal symptoms

Gastrointestinal or general signsAnorexia, vomiting, diarrhea

Neurologic/sensory signsNew ageusia or anosmia

Pediatric/infant-specific signsIrritability, decreased activity, poor feeding, tachypnea, chest retractions, wheezing, cyanosis, apnea episodes; non‑specific signs in infants include lethargy and fussiness